Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound

(March 30, 2026) by Frank Vinluan

Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing activity amid market turbulence from tariffs and war.

Kailera Therapeutics isn’t the only company developing an obesity drug that hits multiple targets for weight loss, but the clinical-stage biotech believes its lead drug candidate can beat other medicines in helping patients shed body weight. With that in-licensed drug now in pivotal testing, Kailera is starting to build its case for investors in the public markets.

Waltham, Massachusetts-based Kailera filed its IPO paperwork after Friday’s market close. As is typical of such initial filings, there are no financial details yet about how many shares the company plans to offer and how much it aims to raise. Kailera has applied for a Nasdaq listing under the stock symbol “KLRA."